BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zhiyu,Tang

第一单位： Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd., Beijing, P.R. China.

作者： Zhiyu,Tang ^[1] ; Xi,Yuan ^[2] ; Rong,Du ^[2] ; Shing-Hu,Cheung ^[2] ; Guoliang,Zhang ^[3] ; Jing,Wei ^[2] ; Yuan,Zhao ^[2] ; Yingcai,Feng ^[4] ; Hao,Peng ^[4] ; Yi,Zhang ^[4] ; Yunguang,Du ^[4] ; Xiaoxia,Hu ^[1] ; Wenfeng,Gong ^[1] ; Yong,Liu ^[1] ; Yajuan,Gao ^[1] ; Ye,Liu ^[4] ; Rui,Hao ^[4] ; Shengjian,Li ^[4] ; Shaohui,Wang ^[3] ; Jiafu,Ji ^[5] ; Lianhai,Zhang ^[5] ; Shuangxi,Li ^[5] ; David,Sutton ^[1] ; Min,Wei ^[4] ; Changyou,Zhou ^[3] ; Lai,Wang ^[1] ; Lusong,Luo ^[6]

作者单位： Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd., Beijing, P.R. China. ^[1] Department of Discovery Biology, BeiGene (Beijing) Co., Ltd., Beijing, P.R. China. ^[2] Department of Chemistry, BeiGene (Beijing) Co., Ltd., Beijing, P.R. China. ^[3] Department of Molecular Sciences, BeiGene (Beijing) Co., Ltd., Beijing, P.R. China. ^[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Surgery, Peking University Cancer Hospital and Institute, Beijing, P.R. China. ^[5] Department of Discovery Biology, BeiGene (Beijing) Co., Ltd., Beijing, P.R. China. lusong.luo@beigene.com. ^[6]